Deflazacort is an oxazoline glucocorticoid clinically used to treat Duchenne muscular dystrophy; it improves motor function and slows progression of the disease. Deflazacort also exhibits anti-fibrotic activity, slowing the progression of myocardial fibrosis in dystrophin-deficient animal models.
| Cas No. | 14484-47-0 |
|---|---|
| Purity | ≥98% |
| Formula | C25H31NO6 |
| Formula Wt. | 441.52 |
| Melting Point | 252-258°C |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | D1624 MSDS PDF |
|---|---|
| Info Sheet | D1624 Info Sheet PDF |
Hoffman EP, Reeves E, Damsker J, et al. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am. 2012 Nov;23(4):821-8. PMID: 23137739.
Silva EC, Machado DL, Resende MB, et al. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy. Arq Neuropsiquiatr. 2012 Mar;70(3):191-5. PMID: 22392111.
Joshi N, Rajeshwari K. Deflazacort. J Postgrad Med. 2009 Oct-Dec;55(4):296-300. PMID: 20083885.
Marques MJ, Oggiam DS, Barbin IC, et al. Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve. 2009 Sep;40(3):466-8. PMID: 19623634.
